Find Oncology Drugs in Phase II Clinical Development in CANADA

Lead Product(s): ZW25

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: J.P. Morgan Securities

Deal Size: $279.0 million Upfront Cash: Undisclosed

Deal Type: MPO January 22, 2020

Details:

The company intends to use the net proceeds to accelerate & expand the global development of ZW25 both as a single agent and in combination with other anti-cancer agents & the clinical development of ZW49.

Lead Product(s): ZW25,Palbociclib,Fulvestrant

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 12, 2020

Details:

Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance. Zymeworks will sponsor the study, and Pfizer will provide palbociclib.